Emerging Sjögren’s Treatments Show Promise in Clinical Trials

Recent updates from a major Sjögren’s-focused medical conference have highlighted encouraging progress in the development of new treatments for this complex autoimmune disease. Researchers and clinicians presented findings from several ongoing clinical trials, many of which are targeting the underlying immune system dysfunction that drives the disease.

Sjögren’s disease can cause a wide range of symptoms, including dryness, fatigue, joint pain, and cognitive difficulties. For many patients, fatigue and brain fog are among the most challenging aspects of daily life. Current treatments mainly focus on symptom relief, making the development of disease-modifying therapies especially important.

At the conference, experts discussed six experimental medications that are currently being studied in clinical trials. These drugs are designed to target specific immune pathways involved in Sjögren’s, including B-cell activity and inflammatory signaling. Some of the therapies mentioned include deucravacitinib, dazodalibep, and ianalumab, each working in different ways to regulate immune system behavior.

One key measure used in these studies is the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), which helps researchers track how active the disease is in different parts of the body. Several of the new treatments have shown improvements in these scores, suggesting they may reduce disease activity.

Importantly, some trials are also beginning to focus on patient-reported outcomes, such as fatigue levels. In one study, a treatment demonstrated a meaningful reduction in fatigue, which is a major priority for many people living with Sjögren’s. This shift toward including patient experiences in research reflects a growing recognition of what matters most to patients.

While these treatments are still under investigation and not yet widely available, the progress is encouraging. These studies represent a move toward more targeted and effective therapies that could improve both symptoms and long-term outcomes. As research continues, patients may soon have more options that go beyond managing symptoms to addressing the root causes of the disease.